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Abstract Expression of oncogenic Ras in UR61 cells (a PC12
subclone) results in neuronal differentiation. We have observed
that the oncoprotein selectively increased the levels of NGFI-A
transcripts, but was unable to induce NGFI-B or c-fos
transcripts. In contrast, nerve growth factor (NGF) elicited a
strong induction of the three immediate early genes (IEGs).
Thus, activation of Ras alone is sufficient for the induction of
NGFI-A by NGF, whereas an additional pathway(s), besides
Ras, is required for the stimulation of NGFI-B and c-fos gene
expression. These results show that the acquisition of a neuronal
phenotype does not correlate with induction of IEG expression.
Additionally, Ras markedly reduces the response of the three
genes to NGF and to other growth factors. This attenuation could
reflect a negative regulatory mechanism acting on signalling
pathways normally stimulated by growth factor receptors.
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1. Introduction
Upon incubation with neurotrophic factors, such as nerve
growth factor (NGF) [1] and ¢broblast growth factor (FGF)
[2], or after expression of the Ras oncogene [3,4], PC12 cells
acquire a phenotype resembling sympathetic neurons. The
neuron-like di¡erentiation of PC12 cells is induced by NGF
through a sustained stimulation of a signalling pathway, the
Ras-MAPK (mitogen-activated protein kinase) cascade [5].
This results in the rapid and transient induction of a set of
genes called immediate early genes (IEGs) which encode sev-
eral protooncogenes and transcription factors [6,7]. Epidermal
growth factor (EGF) and insulin-like growth factor 1 (IGF-1),
which also bind to tyrosine kinase receptors, stimulate prolif-
eration and cause a transient MAPK activation [8], without
causing di¡erentiation of PC12 cells. However, both neuro-
trophic and mitogenic factors induce expression of IEGs in
these cells.
Retinoic acid, a ligand of nuclear receptors which belong to
the steroid/thyroid hormone nuclear receptor superfamily, has
also pronounced e¡ects on PC12 cell proliferation, di¡erentia-
tion and gene expression [9^11]. We have recently shown that
RA attenuates the response of NGFI-B and c-Fos to NGF,
but does not alter NGF induction of NGFI-A [12]. NGFI-A
(also called zif268, egr-1, krox24, TIS8 and D2) codes for a
member of the zinc-¢nger transcriptional activator family [13],
and NGFI-B (also called N10 and nur77) codes for an orphan
receptor member of the steroid/thyroid hormone receptor
superfamily [14].
In this study we have analyzed the e¡ect of Ras on the
expression of c-fos, NGFI-A, and NGFI-B in UR61 cells, a
subclone of PC12 cells which contains a corticosteroid-induc-
ible N-ras oncogene. NGF does not induce neurite outgrowth
in UR61 cells, but incubation with dexamethasone causes ex-
pression of Ras and extensive neurite extension [15]. Our data
show that expression of oncogenic Ras in UR61 cells induces
NGFI-A, but not c-fos or NGFI-B transcripts. In addition,
the three IEGs are strongly induced by NGF and other lig-
ands of tyrosine kinase receptors, and the oncoprotein mark-
edly blocks these responses. These results show that in these
cells the acquisition of a neuronal phenotype does not corre-
late with induction of IEG expression.
2. Materials and methods
2.1. Cell cultures
UR61 cells were cultured as previously described [10,11] in RPMI
medium containing 10% donor horse serum (Quality Biological Inc.)
and 5% fetal calf serum (GIBCO). UR61 cells were derived from
PC12 cells following stable transfection with a plasmid containing
the transforming mouse N-rasVal12 oncogene under control of the
dexamethasone-inducible mouse mammary tumor virus (MMTV) pro-
moter [15].
2.2. RNA extraction and hybridization
Total RNA was extracted from the cell cultures with guanidine
thiocyanate. The RNA was run in 1% formaldehyde-agarose gels
and transferred to nylon-nitrocellulose membranes (Nytran) for
Northern blot analysis. The RNA was stained with 0.02% methylene
blue, and the blots were sequentially hybridized with cDNA probes
for NGFI-A [13], NGFI-B [14] and c-fos [16] labeled by random
oligonucleotide priming. Hybridizations were carried out at 42‡C
with 50% formamide and the most stringent wash was at 42‡C with
0.1USSC-0.1% SDS. Quanti¢cation of mRNA levels was carried out
by densitometric scan of the autoradiograms. The values obtained
were always corrected for the amount of RNA applied in each lane
which was determined by densitometry of the methylene blue stained
membranes.
3. Results
The left panel in Fig. 1 shows that, con¢rming our previous
observations [17], NGFI-A mRNA levels were signi¢cantly
induced in UR61 cells treated with 100 nM dexamethasone
for 8 h. Since dexamethasone treatment did not induce NGFI-
A mRNA levels in parental PC12 cells [12], this result indi-
cates that activated Ras is responsible for stimulation of
NGFI-A gene expression by the steroid in UR61 cells. As
illustrated in the right panel, NGFI-A transcripts were detect-
ably increased at 3 h of dexamethasone treatment, were max-
imal between 8 and 24 h, and returned to basal levels after 36^
48 h. In contrast to the induction of NGFI-A, NGFI-B or
c-fos mRNA remained undetectable upon incubation of UR61
cells with dexamethasone for time periods ranging from 30 min
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to 48 h. These results demonstrate a di¡erential response of
di¡erent IEGs after expression of Ras.
IEG response to NGF was also examined in UR61 cells.
Fig. 2 shows the levels of NGFI-A, NGFI-B and c-fos tran-
scripts. Basal levels were undetectable in the absence of NGF,
but were strongly increased 30 min after NGF treatment.
Thereafter, the three mRNAs decreased rapidly, being barely
detectable at 2 h. Transcription of these genes does not re-
quire ‘de novo’ protein synthesis, and inhibitors of protein
synthesis prolong transcription and stabilize the mRNAs
[18]. Fig. 2 illustrates that NGF stimulation of UR61 cells
in the presence of cycloheximide leads to superinduction of
IEG transcripts, which under these conditions reach the high-
est levels at 2 h. Therefore, although c-fos and NGFI-B
mRNAs were not induced after Ras expression, these mRNAs
showed a normal response to NGF in UR61 cells. To analyze
the e¡ect of activated Ras on the inducibility of IEGs by
NGF, the response to NGF was examined in UR61 cells
treated with dexamethasone for 36 h. This treatment essen-
tially abolished the response to NGF. Expression of Ras was
even able to block the maximally induced levels of NGFI-A,
NGFI-B and c-fos transcripts obtained in UR61 cells incu-
bated with the combination of NGF plus cycloheximide.
Dexamethasone did not reduce NGF inducibility in parental
PC12 cells [12], showing that the repressive e¡ect of the
corticosteroid is due to the expression of oncogenic Ras.
We next tested whether IEG activation by other factors
would be also repressed by oncogenic Ras in UR61 cells.
Fig. 3 shows that treatment with bFGF, EGF or IGF-1 in-
creased NGFI-A transcripts to similar levels as did NGF or
serum. In addition, inducibility by the di¡erent factors was
signi¢cantly reduced after expression of the ras oncogene (left
panel). This attenuation is not restricted to growth factors
since, as shown in the right panel, the response to TPA or
forskolin was also blocked in UR61 cells expressing Ras.
Identical results were obtained for NGFI-B and c-fos, since
their mRNAs were induced by the di¡erent stimuli, but were
undetectable in UR61 cells treated with dexamethasone (data
not shown).
We have previously shown that in PC12 cells RA attenuates
the response of the NGFI-B and c-fos genes to NGF, whereas
it does not alter NGFI-A induction [12]. Therefore, it was of
interest to analyze whether RA could also modulate IEG re-
sponse to Ras. For this purpose, the mRNA levels of NGFI-
A, NGFI-B, and c-fos were determined in untreated control
UR61 cells and in cells incubated for 36 h with dexametha-
sone, RA or both. For each treatment, cells were incubated
with medium alone, NGF and/or cycloheximide. As illus-
trated in Fig. 4, treatment with RA decreased NGFI-B and
c-fos induction by NGF, as well as the superinduction caused
by NGF plus cycloheximide in UR61 cells. These results are
similar to those found in the parental PC12 cells. In addition,
expression of Ras blocks the response to NGF, and both in
the absence and the presence of RA, NGFI-B and c-fos tran-
scripts were basically undetectable in the cells treated with
dexamethasone. Again the response of the NGFI-A gene
was di¡erent from that of NGFI-B or c-fos genes. As illus-
trated in Fig. 5, treatment with RA did not alter basal NGFI-
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Fig. 1. Expression of N-Ras induces NGFI-A, but not NGFI-B or
c-fos expression in UR61 cells. These cells contain the N-rasVal12 on-
cogene under control of the glucocorticoid-inducible MMTV pro-
moter. The left panel shows representative Northern blots of 30 Wg
of total RNA obtained from cells incubated with 100 nM dexame-
thasone (Dx) for 0, 8 and 36 h. The right panel shows the quanti¢-
cation of IEG mRNA levels in cells treated from various intervals
(0, 0.5, 3, 8, 24, 36 and 48 h) with Dx. Data are mean þ S.D. values
and are expressed as percentages of the maximal mRNA values ob-
tained.
Fig. 2. Ras abolishes the IEG response to NGF. UR61 cells were
pretreated with medium alone (Control) or with 100 nM dexametha-
sone (Dx), which induces expression of the N-rasVal12 oncogene, for
36 h. The cells were treated for the last 30 min or 2 h with 50 ng/
ml NGF (N) and/or 5 Wg/ml cycloheximide (X) as indicated. N30,
NGF 30 min; N2, NGF 2 h; XN2, cycloheximide+NGF 2 h; X2,
cycloheximide 2 h. Northern blot analysis was performed with 30
Wg total RNA and labeled NGFI-A, NGFI-B and c-fos cDNA
probes. Representative blots obtained from duplicate cultures for
each treatment are shown.
Fig. 3. In£uence of Ras on IEG response to di¡erent stimuli. UR61
cells were incubated for 36 h in the presence or absence of 100 nM
dexamethasone (Dx), and for the last 30 min with: 50 ng/ml NGF,
17 ng/ml bFGF, 60 ng/ml EGF, 38 ng/ml IGF-1 or 20% fetal calf
serum (FCS) (left panel); or with 50 ng/ml NGF, 100 nM TPA or
10 WM forskolin (Fk) (right panel). Northern blot analysis was car-
ried out with 30 Wg total RNA and a labeled NGFI-A cDNA probe
(lower panels). The upper panels show the quanti¢cation of the
NGFI-A transcripts shown in the lower panels. The data are ex-
pressed as the percent of the maximal mRNA value obtained which
was considered as 100%.
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A mRNA levels or the response to NGF and cycloheximide.
Again, expression of Ras signi¢cantly blocked the induction
of NGFI-A by NGF. This repressive e¡ect was not a¡ected
by RA, as shown by the low levels of NGFI-A transcripts
observed in cells pretreated with the combination of RA
and dexamethasone and stimulated with NGF. Unexpectedly,
incubation with cycloheximide caused a strong induction of
NGFI-A mRNA levels in cells pretreated with RA and dexa-
methasone. These levels were close to the maximal superin-
duced levels in control cells, and were higher than those found
in cells incubated with NGF for 30 min under control con-
ditions. This induction by cycloheximide was not found after
an independent treatment with dexamethasone or RA, and the
combination of both agents was required for the stimulation
of NGFI-A transcripts.
4. Discussion
Expression of oncogenic Ras, which causes neuronal di¡er-
entiation of UR61 cells [15] results in a strong induction of
NGFI-A transcripts. In contrast, expression of Ras was un-
able to induce NGFI-B and c-fos transcripts in these cells.
Although the NGFI-A, NGFI-B and c-fos genes bear similar
expression kinetics following NGF stimulation, and despite
the extensive similarity among the promoter elements in-
volved, their induction must have di¡erent components since
their response to Ras is di¡erent. The lack of c-fos induction
by Ras in UR61 cells [19] is consistent with the ¢nding that no
signi¢cant elevation of c-fos transcripts has been found in
¢broblasts transformed by oncogenic Ras [20]. In contrast
with these observations, it has been described that c-fos tran-
scripts are induced in PC12 cells infected with retrovirus vec-
tors carrying an activated Ha-ras oncogene [21]. This discrep-
ancy might be due to the fact that UR61 cells express N-ras
rather than Ha-ras. Although N-, Ha- and K-ras exhibit a
very high degree of homology, several recent reports support
speci¢c biological roles for the Ras isoforms [22,23].
Our results suggest that activation of the Ras pathway
alone is su⁄cient for stimulation of NGFI-A gene expression
in UR61 cells, whereas additional pathway(s), besides Ras,
appear to be required for stimulation of NGFI-B and c-fos
gene expression. Recent data con¢rm the participation of
more than one signalling pathway in c-fos gene induction by
the neurotrophins. It has been described that both the serum
response element (SRE) [24], and the cyclic AMP response
element (CRE) of the c-fos promoter are critical for NGF
activation of c-fos gene transcription [25]. A NGF-inducible,
Ras-dependent protein kinase, which was identi¢ed as RSK2,
and catalyzes the phosphorylation of CREB (the cyclic AMP
response element-binding protein), was found to trigger this
activation [25,26]. In addition, a very recent report [27] dem-
onstrates that the stimulation of neuronal c-fos expression by
neurotrophins involves at least two signalling pathways: the
Ras-dependent pathway and a calcium/calmodulin-dependent
kinase pathway.
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Fig. 5. RA modulates the in£uence of Ras on NGFI-A expression.
UR61 cells were ¢rst incubated for 36 h under control conditions or
in the presence of 100 nM dexamethasone (Dx), 1 WM RA, or the
combination of both. The cells were then treated as in Fig. 4 with
NGF (N) or cycloheximide (X). N30, NGF 30 min; N2, NGF 2 h;
XN2, cycloheximide+NGF 2 h; X2, cycloheximide 2 h. Northern
blot analysis was performed with total RNA and a labeled NGFI-A
cDNA probe. The Northern blot shown in the lower panel was
quantitated and the data are expressed in the upper panel as the
percent of the maximal mRNA levels obtained in cells incubated
with NGF and cycloheximide. Similar results were obtained in an
independent experiment performed with duplicate cultures for each
treatment.
Fig. 4. Combined e¡ects of NGF, retinoic acid (RA) and Ras on
IEG expression in UR61 cells. The cells were treated with medium
alone (Control), 1 WM RA or 100 nM dexamethasone (Dx) for 48
h. For the last 30 min or 2 h the cells were incubated with 50 ng/ml
NGF (N) and/or 5 Wg/ml cycloheximide (X) as indicated. -, control;
N30, NGF 30 min; N2, NGF 2 h; XN2, cycloheximide+NGF 2 h;
X2, cycloheximide 2 h. Northern blot analysis was carried out with
30 Wg total RNA and labeled NGFI-B (upper panel) and c-fos (bot-
tom panel) cDNA probes. The blots were quantitated by densitome-
try, and the values obtained were corrected for the amount of RNA
applied to each lane. The data for each mRNA are expressed as the
percent of the maximal superinduced levels (obtained in cells incu-
bated with NGF and cycloheximide), which were arbitrarily set to
100%. The data represent the mean values þ standard deviation ob-
tained from two independent experiments performed in duplicate.
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The participation of more than one pathway in the induc-
tion of NGFI-B and c-fos by NGF would be also compatible
with the e¡ect of RA on this response. Since RA does not
alter NGFI-A induction by NGF, activation of the Ras path-
way would not be repressed by RA. In contrast, treatment
with RA would reduce the activity of the Ras-independent
pathway stimulated by NGF, allowing a partial induction
through Ras, and resulting in a decreased response of the
NGFI-B and c-fos genes to the neurotrophin.
A previous study has shown that expression of Ras in
UR61 cells results in inhibition of NGF-induced c-fos tran-
scriptional activation [19]. Our results demonstrate that at-
tenuation of the NGF response by Ras is not restricted to
c-fos but is a more general property of other IEGs, since
the response of NGFI-B and NGFI-A to NGF is also
blocked. Furthermore, this attenuation is extensive to the ac-
tion of other growth factors. Among the growth factors lig-
ands of tyrosine kinase receptors tested, NGF and bFGF
induce PC12 cell di¡erentiation, whereas IGF-1 and EGF
cause cell growth. However, all of them induced transcripts
of the three IEGs with a similar potency, and their action was
blocked by Ras in UR61 cells. Because the Ras protein is
involved in the signalling pathway of tyrosine kinase recep-
tors, this attenuation could re£ect a negative regulatory mech-
anism acting on signalling pathways normally stimulated by
growth factor receptors. Since the induction of the three IEGs
by serum and compounds that stimulate protein kinase C and
protein kinase A was also repressed by Ras, these stimuli and
the growth factors likely share at least some of the pathways
involved in these processes. In this respect, all growth factors
and compounds analyzed can activate the MAPK/ERK path-
way, and it is known that some proteins that are implicated in
the Ras pathway, such as Raf or the guanine nucleotide ex-
changer Sos, can be phosphorylated and inactivated by
MAPK [28,29]. Also, as a possible step in the desensitization
mechanism, some tyrosine kinase receptors can bind and be-
come phosphorylated by MAPK [30].
It has been reported that RA can increase the expression of
NGFI-A in some cell types but not in others [31,32]. The lack
of response has been attributed to the presence of nuclear
proteins responsible for cell-type speci¢c suppression, which
might be involved in the unresponsiveness of the NGFI-A
gene to RA in PC12 cells. This is supported by the ¢nding
that, in UR61 cells, RA is able to induce NGFI-A mRNA
levels in the absence of protein synthesis, a condition in which
putative suppressor proteins with a short half-life could be
removed. In any event, this removal would not be su⁄cient
by itself, because the e¡ect of RA was only observed after
expression of Ras. The modulation of the IEG response shows
the existence of a complex cross-talk between the Ras and RA
signalling pathways which could have important consequences
in PC12 cell proliferation, di¡erentiation or function. Inde-
pendently of the mechanism(s) by which RA cooperates
with Ras to induce NGFI-A expression when protein synthe-
sis is blocked, this e¡ect is not a general property for all IEGs,
since under the same conditions stimulation of NGFI-B or c-
fos was not observed. This ¢nding again demonstrates the
divergent regulation of NGFI-A as compared to the two other
IEGs.
Induction of IEG expression is assumed to play a key role
in proliferation and neuronal di¡erentiation. However, our
data show that NGF elicits a IEG response in the morpho-
logically unresponsive UR61 cells which is identical to that
observed in the parental PC12 cells where the neurotrophin
promotes neurite outgrowth. Moreover, in UR61 cells expres-
sion of oncogenic Ras, which causes extensive neuronal di¡er-
entiation, does not produce transcription of the c-fos and
NGFI-B genes and blocks induction by growth factors. These
results show that IEG expression does not correlate directly
with the development of a neuronal phenotype in these cells.
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